目的探讨胃癌患者手术前后血清TSGF、AFP及HER-2/neu ECD的变化及意义,为肿瘤标志物水平预测手术预后提供临床依据。方法对本院82例行胃癌根治术的患者进行回顾性分析:(1)分析术后3个月、6个月、1年的血清肿瘤特异生长因子TSGF、甲胎蛋白AFP及表皮生长因子受体HER-2/neu ECD降低情况;(2)不同临床病理参数的TSGF、AFP及HER-2/neu ECD降低情况;(3)肿瘤标志物不同降低水平的胃癌复发和累计生存率的影响。结果 (1)术后3个月后,血清TSGF、AFP及HER-2/neu ECD水平均降低,且与术后6个月、1年差异有统计学意义;(2)除了年龄外,其余病理参数在同一分级的降低情况差异均有统计学意义;(3)除了术后3个月外,低降低组的复发率高于高降低组,且术后900 d累计生存率低于高降低组,除TSGF(P<0.01,Log-rank检验),其余两个指标为P<0.05。结论血清TSGF、AFP及HER-2/neu ECD手术前后的变化不仅可用来评价治疗效果,也可用来衡量术后的复发和生存情况。 Objective To investigate the changes and significance of serum TSGF, AFP and HER-2 / neu ECD before and after operation in patients with gastric cancer and to provide a clinical basis for predicting the prognosis of the surgery. Methods A retrospective analysis was performed on 82 patients undergoing radical gastrectomy in our hospital: (1) The levels of serum tumor-specific growth factor (TSGF), alpha-fetoprotein (AFP) and epidermal growth factor (EGF) at 3 months, 6 months and 1 year (2) Decreased TSGF, AFP and HER-2 / neu ECD with different clinicopathological parameters; (3) The effects of different levels of tumor markers on the recurrence and cumulative survival of gastric cancer. Results (1) Serum levels of TSGF, AFP and HER-2 / neu ECD decreased at 3 months after operation, and there was significant difference between them at 6 months and 1 year after operation. (2) Except for age, (3) Except for 3 months after operation, the recurrence rate of the low-reduction group was higher than that of the high-reduction group, and the cumulative survival rate at 900 days after operation was lower than that of the high-grade group Group, except TSGF (P <0.01, Log-rank test), the other two indicators were P <0.05. Conclusion The changes of serum TSGF, AFP and HER-2 / neu ECD before and after surgery can not only be used to evaluate the therapeutic effect, but also be used to measure the postoperative recurrence and survival.